The system involves one or two thin leads implanted under the skin, which deliver pulses of electricity to the nerves to block or reduce pain signals.
The FDA recently approved the 60-day device for a broader range of applications, including treatment in the head, neck and front of the torso, SPR said in an Oct. 19 news release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.